After two high-profile late-stage trial flops, AstraZeneca has finally scored a victory for Imfinzi and ill-fated tremelimumab in newly diagnosed metastatic non-small cell lung cancer (NSCLC). But in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results